AbCellera acquires TetraGenetics for $12.5M upfront to boost antibody discovery

AbCellera Biologics Inc.

Upfront cash consideration of $12.5M; additional technical, development, and commercial milestones possible.
TetraGenetics specializes in recombinant ion channels, GPCRs, and other transmembrane proteins.
Acquisition integrates TetraGenetics' protein expression platform into AbCellera's antibody discovery stack.
Deal aims to unlock antibody therapies against difficult-to-drug transmembrane targets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.